POINT Biopharma and SCINTOMICS Announce License Agreement
TORONTO and MUNICH, Germany, March 10, 2020 -- POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of … READ MORE
Munich/Berlin, February 2020
PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics
Funding will be used for phase I / phase II trials of the lead program PentixaTher/ PentixaFor
WÜRZBURG, Germany -- PentixaPharm announced today to have secured € 15 million In a series A financing round led by ELSA Eckert Life… READ MORE
Munich, June 2019
TUM Presidential Entrepreneurship Award 2019 went to Scintomics
This year the Technical University of Munich (TUM) has presented its Presidential Entrepreneurship Award to Scintomics GmbH.
>> The company develops, produces and markets innovative radio-pharmaceutical and nuclear medicine technologies for tumor diagnostics and tumor therapy. Scintomics has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006. In recent years Scintomics has been capturing increasing shares of the pharmaceuticals sector with highly-innovative radio diagnostics and therapeutic solutions, most of which have been developed and patented at TUM. Scintomics accompanies the entire process from production all the way to regulatory approval of new radio-pharmaceuticals. TUM is also the hub of the expertise behind the company’s interdisciplinary entrepreneurial strategy: Its founder Prof. Hans-Jürgen Wester holds the TUM Chair of Pharmaceutical Radiochemistry, while CEO Saskia Kropf is a TUM graduate in Mechanical Engineering.<< (TUM press release)
"We are very pleased that this year the Technical University of Munich (TUM) has presented its Presidential Entrepreneurship Award to Scintomics GmbH. Many innovative TUM spin-offs applied and competed for the 10.000 Euro endowed award. We are honoured to have received this award and proud of the strong partnership with TUM”, said Hans-J. Wester, founder of Scintomics. "We want to thank TUM for this award, the great cooperation and for the confidence in the performance capability of our company.”
Munich, June 2019
Andrea Maugg appointed CEOs
Andrea Maugg has been appointed Chief Executive Officer of Scintomics and ATT (Scintomics Molecular/Applied Theranostics), with effect from July 2019.
Saskia Kropf and Dorothea Wester will continue as CEO of Scintomics, and will focus on business development, licensing and finance.
Munich, December 2019
The year is drawing to a close. We would like to take this opportunity to thank you for your trustand wish you a Merry Christmas and a successful New Year! Yours Scintomics/ATT – Team
EANM Barcelona, October 2019
Sarah Baum (left; Radiochemist and Product Manager siGRP and SiFA-based tracers) and Alina Biberacher (right, Sales Dept.) at the att-EANM booth.
At the EANM 2019 att/Scintomics announced that it has started with the installation of siGRP modules.
att/Scintomics has completed the necessary technical preparations of the new siGRP module and has already started with the installation of siGRP modules.
(R&D grade; (GMP soon)
Training Courses: Production of F-18-siPSMA and F-18-siTATE
The first training course was held in Fürstenfeldbruck/Bavaria in September. Further courses are helt monthly and will cover:
- siGRP module: installation, production, service
- siPSMA: chemsitry and radiopharmacy
- siTATAE: chemsitry and radiopharmacy; - SiFA-Tracers: what is in the pipeline?
Munich/Berlin, May 2019
Scintomics and 1717 Life Science Ventures Team up in the Joint Venture PENTIXAPHARM to Develop CXCR4-Targeted Theranostics
>> Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
“We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”